In the DAISY trial, ORR of 30.6% in T-DXd treated patients (n = 38) with HER2-null breast cancer
New answer by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty (April 16, 2023)
This question begs another update for the ASCO/CAP guidelines on the description of HER2 positivity/negativity and/or HER2 low expressors. The first ASCO/CAP guidelines on HER...